New York University

Igen, Inc.

Other

Kollmorgen Corporation

Neville Robert Kallenbach

Zhigang Liu

Chunhui Zhou

Peter S Kim

Anne Young

Young-Tae Chang

George J Todaro

Nadrian C Seeman

Harvey Rubin

Jaeki Min

Victor N Morozov

Junghuei Chen

Robin M Hochstrasser

Filbert Totsingan

Paul A Cornelius

Novel s-triazine compounds are disclosed that have a formula represented by the following: L, L, L, R, R, R, R, R, R, and Rare as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.

s-Triazine compounds, pharmaceutical compositions and methods of using the same

Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L, L, L, Z, R, R, Rand Rare as described herein. The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provided by standard antibiotics. 

Dendrimeric peptides, pharmaceutical compositions and methods of using the same

Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

Novel s-triazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.

s-Triazine compounds, pharmaceutical compositions and method of using the same

Eyewear which provides a visual stimulation to the wearer while permitting the wearer to maintain a degree of normal sight. The eyewear may include a frame securing a first viewing zone which is responsive to an external signal for modulation of a visual characteristic thereof and a second viewing zone which permits the wearer to maintain a degree of normal sight through that zone. Alternatively, a single zone is responsive to an external signal while nevertheless permitting the wearer to maintain an degree of normal sight.

Visual entertainment eyewear system and apparatus therefor

Process for producing an immunoproximity catalyst for a chemical reaction. Chemical reactions in which the immunoproximity catalyst can be used are also disclosed.

Production of immunoproximity catalysts

Process for producing an antibody catalyst for a chemical reaction. Chemical reactions in which the antibody catalyst can be used are also disclosed.

Production of antibody catalysts

The invention discloses an n-connected closed covalent three-dimensional structure of oligonucleotides, n being at least 3, and methods for making and using same.

Multiply connected, three-dimensional nucleic acid structures

A novel irradiation process and products made thereby. The process treats biological media such as blood fractions, genetically engineered protein products and vaccine preparations. The process photolyzes nucleic acids in preference to proteins in the media, e.g., it inactivates DNA- or RNA-containing pathogens while leaving the proteins substantially intact or functional. In general, the process comprises irradiating the medium with pulsed light of wavelength and flux selected so that (1) the nucleic acids in their ground state absorb radiation and thereby rise to an excited state or states, (2) the nucleic acids in their excited states absorb radiation and thereby rise to higher energy states and undergo photolysis, and (3) the proteins in their ground or their excited states do not absorb sufficient radiation to undergo substantial photolysis. It is surprising and unexpected that nucleic acids in their excited states undergo efficient photolysis whereas proteins under the same conditions in the same medium are kept substantially intact.

Growing community of inventors

Philadelphia, PA, United States of America

Neville Robert Kallenbach